Christine Mikail Cvijic Sells 739 Shares of Neurogene (NASDAQ:NGNE) Stock

Posted by Geri Gentry on Jul 2nd, 2026

Neurogene Inc. (NASDAQ:NGNE – Get Free Report) CFO Christine Mikail Cvijic sold 739 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $34.06, for a total transaction of $25,170.34. Following the transaction, the chief financial officer owned 92,901 shares of the company’s stock, valued at approximately $3,164,208.06. This trade represents a 0.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total transaction of $141,404.02.
On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Stock Up 4.3%

Neurogene stock traded up $1.46 during mid-day trading on Thursday, hitting $35.34. The company’s stock had a trading volume of 363,205 shares, compared to its average volume of 174,652. The stock has a market capitalization of $558.37 million, a P/E ratio of -7.77 and a beta of 1.68. Neurogene Inc. has a twelve month low of $15.93 and a twelve month high of $37.27. The stock’s fifty day moving average price is $29.05 and its two-hundred day moving average price is $23.14.

Neurogene (NASDAQ:NGNE – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). Equities analysts expect that Neurogene Inc. will post -5.63 earnings per share for the current year.

Institutional Investors Weigh In On Neurogene

Several hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in Neurogene by 210.0% during the 1st quarter. Renaissance Technologies LLC now owns 43,400 shares of the company’s stock valued at $875,000 after acquiring an additional 29,400 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Neurogene by 12.8% in the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after acquiring an additional 2,950 shares during the last quarter. Virtus Investment Advisers LLC boosted its position in Neurogene by 128.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock valued at $262,000 after purchasing an additional 7,138 shares during the last quarter. Logos Global Management LP acquired a new stake in Neurogene during the fourth quarter valued at $4,017,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Neurogene in the fourth quarter valued at about $575,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NGNE. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a report on Tuesday, June 9th. Guggenheim started coverage on shares of Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price on the stock. UBS Group set a $70.00 price target on shares of Neurogene in a report on Wednesday, June 3rd. Finally, Rodman & Renshaw started coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $84.83.

View Our Latest Stock Analysis on Neurogene

About Neurogene

(Get Free Report)

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.